Amid the growing infection of the coronavirus, everyone is eagerly waiting for its vaccine. We are also succeeding to a great extent in the war against the Corona epidemic and the country is just a step away from success in the vaccine race. Three vaccine candidates in the country are undergoing the third phase of human trials, while the final phase trials of Sputnik-V, the world's first vaccine produced in Russia, have also been approved. Overall, this week has proved to be very crucial for the Corona vaccine in the country and good news has come out from all sides. If the vaccine company and institutions believe that success is just a step away. It is expected that the year 2021 will begin with success in the vaccine. We currently know what happened in the country this week regarding the corona vaccine:
Desi vaccine Covaxin gets Phase-3 trial approval
Covaxin, the first indigenous vaccine to be developed by Bharat Biotech Company with the help of the Indian Council of Medical Research (ICMR), has got permission for the third phase of human trials. The company will try it at around 20,000 volunteers. The clinical study will take time, but it is expected that the vaccine will be available for vaccination in the next few months.
Russian vaccine Sputnik-V trial also gets green signal
The trial of Sputnik-V, Russia's first corona vaccine, has also been approved by the Indian drug Niamak DCGI. Earlier, DCGI had stopped large-scale last-stage trials, arguing that there has not been a large-scale vaccine trial on humans in Russia or other countries. Amending the protocol on the recommendation of the expert committee, the second and third phase trials have been allowed. According to reports, the second phase of the trial will take place with 100 Volunteers.
Kovishield's Phase 3 trial soon
The Oxford and AstraZeneca vaccine is being developed by the Indian giant vaccine maker Serum Institute of India under the name 'Kovishield'. This vaccine has shown excellent results in the second phase trial. ICMR is under trial in India under its supervision. Phase III trials of this vaccine have been approved and will start soon.
Partnership with the US and Germany for antibody therapy
Indian vaccine manufacturer Serum Institute of India has tied up with German giant pharma company Merck and New York-based nonprofit health research organization IAVI for treating corona with monoclonal antibodies (mAbs). The three are working together on monoclonal antibodies (mAbs). Monoclonal antibody drugs will be given as antibodies to improve the immune system of the body in advance. This makes the human immune system more efficient so that it can fight the disease.